Biopharmaceuticals / Clinical-Stage Drug Development
Strategic Profile
The company has license and collaboration agreements with Janssen Pharmaceuticals Inc. for mGlu2 PAM compounds and with Indivior PLC for GABAB PAM compounds. Lead drug candidates include ADX71149, developed in partnership with Janssen for epilepsy treatment, and dipraglurant for Parkinson's disease levodopa-induced dyskinesia and post-stroke/TBI recovery. The partnership model provides both clinical validation and funding runway.
Cyborg Score Rationale
Addex operates as an early-stage biotech with strong academic partnerships (Janssen, Indivior) and a well-defined allosteric modulator platform. However, the company is pre-commercial with limited revenue, very few employees, and minimal cash position. Clinical-stage risks are substantial.
Top Insights
2024 revenue was $465,700, representing a 74.6% decline year-over-year
Market cap is approximately $14.7M as of recent data
Company operates with minimal headcount of 2 full-time employees
Lead program Dipraglurant is in Phase 1 trials; ADX71149 and GABAB PAM candidates in development for multiple indications
Named Competitors
Allosteric Modulator Programs — Collaborator on mGlu2 PAM compounds
GABAB PAM Programs — Collaborator on GABAB PAM development for addiction and CNS